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Abstract
Background: It has been shown that dendritic cells (DCs) and fractalkine play a role in accelerating progression of
the inflamed atherosclerotic lesions and plaque rupture. We evaluated the numbers and functional changes of DCs
and its subsets in human type 2 diabetes with or without unstable angina pectoris (UAP).
Methods: The study population consisted of 39 diabetic patients (DM:18 without CAD; DM + UAP: 21 with UAP),
18 non-diabetic UAP patients (UAP), and 15 healthy control (Normal). Peripheral blood DCs and its subsets were
measured by three color flow cytometry. Serum levels of fractalkine, IL-12, and IFN-a were also measured. The
functional status of the monocyte-derived DCs was analyzed by flow cytometry and allogeneic mixed T
lymphocytes reaction.
Results: The percent and absolute numbers of DCs and mDC within the total leukocyte population was similar for
Normal and DM, while significantly lower in DM + UAP. pDC numbers were not significantly altered. Serum
fractalkine in DM + UAP was highest among the four groups (p = 0.04 vs. UAP, p = 0.0003 vs. DM, p < 0.0001 vs.
Normal). Circulating mDC inversely correlated with serum fractalkine (r = -0.268, p = 0.01) level. Compared with DM
and UAP, the costimulatory molecules CD86 and proliferation of T cells stimulated by DCs were significantly
increased in DM + UAP group.
Conclusions: Our study suggested that increases in the fractalkine level and the number and functional changes
of blood DCs might contribute to diabetic coronary atherosclerosis and plaque destabilization.
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Introduction
Atherosclerosis and its clinic consequence, such as cor-
onary artery disease (CAD), are the main cause of death
in diabetic patients[1]. Coronary atherosclerotic plaques
in diabetics tended to develop earlier and be more
extensive and unstable compared with none diabetes
[2,3]. Inflammation and immune reactions play a crucial
role in the development of atherosclerosis and also dia-
betes associated vascular complications[4-6]. Immune
responses induced by apoproteins and active moieties
localized in the lipid fraction of the atheroma have been
suggested to be involved in the inflammation response
[7]. These antigens would attract antigen-presenting
cells (APCs) and subsequent T cells activation in athero-
sclerotic plaque. Dendritic cells (DCs), the most potent
APCs with the unique ability to initiate a primary
immune response to certain antigens[8], were recently
found to be markedly increased in atherosclerotic pla-
ques[9-11] and were actively related in the process of
atherosclerosis. Activated DCs regulate effector T cells
which can kill plaque-resident cells and damage the pla-
que structure.
The chemokine family is thought to contribute signifi-
cantly to the pathogenesis of atherosclerosis, from early
plaque development to plaque rupture. The recently
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discovered chemokine fractalkine (FKN) and its receptor
CX3CR1 are particularly interesting because of its
potential pathophysiological role in atherosclerosis
[12-14]. Fractalkine exists in two forms: the membrane-
anchored multidomain protein which is expressed pri-
marily on the surface of activated endothelial and
smooth muscle cells, promoting the retention of mono-
cytes and T cells, and the soluble form as a chemotactic
stimulus, which strongly induces inflammation cells. It
has recently shown that the level of FKN/CX3CR1 is
increased in coronary artery disease, and may be related
to plaque rupture[15,16]. In addition, a recent study[17]
has shown that fractalkine is an important chemokine
for accumulation of DCs in atherosclerotic plaque. Defi-
ciency of the fractalkine receptor CX3CR1 resulted in
decreased atherosclerosis and a decreased number of
DCs in atheromas.
To the best of our knowledge, little is known about
the expression of FKN in diabetic patients, and the role
of DCs and FKN in human type 2 diabetes with or with-
out CAD, particular in unstable coronary disease,
remains unclear. We hypothesized that microenviron-
ment in diabetes might result in changes of circulating
DCs numeration and function, leading to the accelerated
progression of diabetes-associated atherosclerosis. We
have, therefore, characterized and compared circulating
DCs subsets and FKN between type 2 diabetic patients
with or without CAD and non diabetic controls. The
maturation status and functional ability to stimulate T
cell of DCs were also evaluated.
Methods
Subjects
The study population consisted of 39 diabetic patients
with (DM + UAP, n = 21) or without (DM, n = 18)
unstable angina pectoris (UAP) and 18 non-diabetic
patients with UAP. They all underwent coronary angio-
graphy for the diagnosis of CAD in the Department of
Cardiology, Zhongshan Hospital, Fudan University,
Shanghai. UAP was defined as having ischemic chest
pain at rest within the preceding 48 h, transient ST-T
segment depression, angiographically verified at least
one coronary lumen diameter narrowing > 50%, and no
positive serum troponin I (> 0.04 ng/ml). The diagnosis
of type 2 diabetes was made according to the criteria of
the American Diabetes Association (ADA,2004). Patients
who had acute or recent myocardial infarction, periph-
eral artery disease, type 1 diabetes, autoimmune dis-
eases, malignancies, chronic or acute infections, asthma,
severe heart failure (NYHA class 3 and 4) and advanced
liver or renal diseases were excluded. In addition, 15 age
and body mass index matched healthy subjects with
neither diabetes mellitus nor any of the components of
the metabolic syndrome were studied as Normal group.
Blood were obtained into EDTA tubes from all sub-
jects via antecubital venepuncture soon after admission.
The protocol was approved by the hospital Ethics Com-
mittee and written informed consent was obtained from
all patients. The study was performed according to the
principles of the Declaration of Helsinki.
Biochemical analysis
White blood cell, serum cholesterol, triglycerides and
glucose were measured according to routine protocols.
Serum HbA1c was determined by HPLC using the
BioRad Variant System. The serum level of FKN was
analyzed using enzyme-linked immunosorbent assay kits
(DY365 DuoSet System, R&D Systems) according to the
manufacturer’s instructions. The serum level of IL-12
and IFN-a were assayed by ELISA (Bender MedSystems,
Austria).
Monoclonal antibodies
Phycoerythrin (PE)-conjugated CD11c, PE-conjugated
anti-IL-3 receptor a chain (CD123), peridinin chloro-
phyll protein (PerCP)-conjugated anti-HLA-DR, fluores-
cent isothiocyanate (FITC)-conjugated lineage cocktail 1
(lin1) and CD86-FITC were purchased from Becton
Dickinson (San Jose, CA, USA). The lin1 contains
monoclonal antibodies (mAbs): CD3 (T cells), CD14
(monocytes/macrophages), CD16 (natural killer cells),
CD19 (B cells), and CD56 (natural killer cells). PE-con-
jugated isotype control murine mAbs were obtained
from Becton Dickinson.
Enumeration of peripheral blood DC
Peripheral blood cells, obtained from the subjects in a
prospective manner, were analyzed by three-color flow
cytometry as we published previously[18]. Briefly, 200 μl
blood was incubated with PE-, PerCP-, and FITC-conju-
gated mAbs for 20 min at room temperature. The ery-
throcytes were then lysed with FACS lysing solution
(Becton Dickinson). After washing with FACS flow, the
stained cells were analyzed with a FACS Caliber flow
cytometer and the CellQuest Pro software (Becton Dick-
inson). To gate Lin1- HLA-DR + cells, whole peripheral
blood cells were stained with anti-HLA-DR mAb and
the Lineage Cocktail (Figure 1). In the gated cells we
further defined the expression of CD11c and CD123 to
determine the two distinct DC lineages. mDC and pDC
were defined as Lin1-HLA-DR + CD11c + and Lin1-
HLA-DR + CD123 + , respectively (Figure 1). The num-
ber of total white blood cells in the samples was deter-
mined using an automated cell counter. CD11c or
CD123 conjugated with PE was used for identification
of the mDC and pDC subsets. Absolute numbers of
mDC and pDC were calculated from the white blood
cell count multiplied by the proportion of each subset
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within the white blood cells. The percentage of mDC
and pDC was derived from the total number of DCs as
determined by flow cytometric analysis.
Generation of Dendritic Cells from Monocytes
We used monocyte-derived DCs to access their matura-
tion and functional activation status. Twenty ml of
blood each was collected from subjects of the four
groups. Isolation of peripheral blood mononuclear cells
and generation of dendritic cell was performed as we
described before[19]. Briefly, blood was diluted 1:2 in
PBS layered over Histopaque 1077 (Sigma, USA) and
centrifuged for 30 min at 2000 rpm at room tempera-
ture. The interface was recovered and washed three
times in PBS. CD14 + PBMC were purified by using
CD14 + immunomagnetic micro beads (Miltenyi Biotech
GmbH, Germany) and incubated in RPMI-1640 medium
supplemented with GM-CSF (100 ng/mL) and IL-4 (50
ng/mL) in six-well tissue culture plates at 37°C and an
atmosphere of 5% CO2. The medium was replaced every
2 days. After seven days, the cultures developed an
adherent monolayer and clusters of DC colonies.
Evaluation of maturation state of DCs
We examined the expression level of CD86 to access the
maturation state of DCs. DCs(1 × 106 cells) were harvest
and blocked with 10% normal goat serum for 15 min at
4°C, washed and then stained with FITC-conjugated
antibodies against CD86 for 30 min at 4°C. Cells stained
with the appropriate isotype-matched IgG were used as
negative controls. After immunofluorescence staining,
cells were analyzed by FACS Calibur using CellQuest
software.
Dendritic cell-induced T cell response
For the mixed lymphocyte reaction, T lymphocytes were
isolated from peripheral blood by human T cell recovery
immunocolumn kit (Cedarlane Laboratories Ltd,
Figure 1 Detection of fractions of peripheral blood dendritic cells (DCs) by standardized 3-color flow cytometry. Peripheral blood
samples were collected and the cells were stained with PerCP-conjugated anti-HLA-DR, PE-conjugated anti-CD11c or anti-IL3a (CD123), and
FITC-conjugated lineage markers (lin1) containing anti-CD3, CD15, CD16, CD19, CD20, and CD56. After lysis of erythrocytes, the cells were
analyzed by three-color flow cytometry. A: Events excluding debris and dead cells (R1); B: cells were gated on region R1, a dot blot of lineage
marker (x axis) versus HLA-DR (y axis) was used to define the region of Lin-cells (R2); (C) pDC was defined as Lin1-, HLA-DR + , and CD123 + (R4);
(D) mDC was defined as Lin1-, HLA-DR + , and CD11c + (R5). FITC: fluorescein isothiocyanate; FSC-H: forward scatter; PE: phycoerythrin; mDC:
myeloid dendritic cell; pDC plasmacytoid dendritic cell.
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Canada). MLRs were conducted in 96-well flat-bottom
culture plates. Before mixed, DCs was pretreated by
mitomycin (150 μmol/L) for 1 hour at 37°C. These cells
were then cultured with 2 × 105 T cells in 200 μL com-
plete culture medium at 1:5, 1:10, 1:50 and 1:100 DCs:T
cells ratio. After 96 hours, 50 μL culture supernatants
were collected, stored at -70°C, and analyzed by ELISA
for production of IL-2, a marker of T-cell activation.
Then 50 μL fresh medium containing 1 μCi of [3H] thy-
midine were added. After 16 hours, the cells were har-
vested onto filter paper, and the incorporation of [3H]
thymidine was determined by scintillation counting.
Statistical analysis
All statistical analyses were performed using SPSS for
Windows 13.0 (SPSS Inc., Chicago, Illinois). Data are
presented as frequencies and percentages for categorical
variables and mean ± SD for continuous variables,
unless otherwise indicated. Statistical analyses were per-
formed with the unpaired Student t test/Mann-Whitney
U test or one-way ANOVA when indicated and Chi
square test to compare the differences of two groups.
The correlation between variables was analyzed by linear
regression analysis. The p values less than 0.05 were
considered to indicate statistical significance.
Results
Study population and clinical characteristics
There was no statistical difference among four groups
with regard to age, gender, BMI, HDL-C and white
blood counts. Triglyceride, total and LDL-cholesterol
levels in the DM, UAP and DM + UAP are higher
than that of the Normal. There was no statistical
difference between the two groups of DM and DM +
UAP in terms of duration of diabetes, fasting blood
glucose and serum HbA1c. Medication using among
the groups of DM, UAP and DM + UAP was similar
before admitting and blood taken, particularly in the
use of anti-platelet therapy, angiotensin-converting
enzyme antagonists, or statins. The demographic
details of the populations studied are given in
Table 1.
Concentration of Circulating sFKN and Other Markers of
Inflammation
The results showed that mean serum FKN level was 477
± 189 pg/ml in the normal subjects, 572 ± 165 pg/ml in
diabetic patients without CHD, 729 ± 145 pg/ml in
non-diabetic patients with UAP, and 943 ± 365 pg/ml in
diabetic patients with UAP. Mean FKN level of DM +
UAP group was not only higher than the group of UAP
(p = 0.04), but also than that of DM group(p = 0.0003).
It was also higher in UAP than DM group (p = 0.03).
On the contrary, mean FKN level of DM was not differ-
ent from the Normal.
Serum IL-12 levels were significantly higher in the
DM, UAP and DM + UAP groups than in the Normal
group (Table 2), and were significantly higher in the
DM + UAP group than in the DM and UAP groups
(p = 0.01 and 0.001 respectively). On the other hand,
there were no significant differences in the serum inter-
feron-a level among the 4 groups (Table 2).
Table 1 Study population and clinical characteristics
Normal (n = 15) DM (n = 18) UAP (n = 18) DM + UAP (n = 21)
Age(y) 54.2 ± 11.4 56.2 ± 8.2 57.5 ± 10.5 55.3 ± 11.2
BMI(kg/m2) 23.7 ± 1.3 24.2 ± 5.3 25.1 ± 3.6 24.6 ± 4.1
Hypertension(n) 0 12* 14* 18*
Diabetes duration(y) — 3.9 ± 1.0 — 4.1 ± 0.8
TC(mmol/l) 3.1 ± 0.5 4.6 ± 1.4* 4.7 ± 2.0* 4.9 ± 1.8*
LDL-C(mmol/l) 1.6 ± 0.4 2.9 ± 0.7* 3.1 ± 0.8* 3.0 ± 1.5*
HDL-C (mmol/l) 1.2 ± 0.5 1.2 ± 0.7 1.1 ± 0.8 1.2 ± 0.6
TG (mmol/l) 1.3 ± 0.7 2.2 ± 1.8* 1.9 ± 1.5* 2.0 ± 1.6*
WBC(× 109) 5.9 ± 0.9 7.2 ± 0.8 7.5 ± 0.8 6.8 ± 1.0
Fasting glycaemia(mg/ml) 4.6 ± 0.7 8.5 ± 2.3#* 5.2 ± 1.2 8.1 ± 1.7#*
HbA1c(%) 4.4 ± 0.88 8.4 ± 2.5#* 5.1 ± 1.1 7.8 ± 1.8#*
Medications
Statins 0 16 18 20
Aspirin 0 16 18 21
Fibrates 0 1 0 1
ACE inhibitor/ARB 0 13 14 17
Results are expressed as mean ± SD. Normal: normal control subjects; DM: type 2 diabetic patients without CAD; UAP: non-diabetic patients with unstable angina
pectoris; DM + UAP: type 2 diabetic patients with UAP; ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker. *p < 0.05 versus Normal; #p <
0.05 versus UAP.
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Frequency of circulating total DCs and DCs subsets
The percent and absolute number of DCs within the
total leukocyte population was similar in type 2 diabetic
patients without CAD (0.27 ± 0.09% and 1.98 ± 0.64 ×
107/L) and the Normal controls (0.29 ± 0.10% and 2.04
± 0.71 × 107/L). Also no differences were found in the
number of mDC and pDC between the two groups
(mDC, 0.23 ± 0.07% and 1.62 ± 0.53 × 107/L versus 0.24
± 0.07% and 1.59 ± 0.46 × 107/L; pDC, 0.05 ± 0.02%
and 0.35 ± 0.17 × 107/L versus 0.06 ± 0.03 and 0.38 ±
0.21 × 107/L) (Figure 2). The ratio of mDC:pDC was
also unchanged with mDC comprising the vast majority
of DCs.
However, the percentage and absolute number of total
DCs was significantly lower in diabetic patients with
UAP compared to those without CAD (0.17 ± 0.07 ver-
sus 0.27 ± 0.09%, p = 0.0003; 1.14 ± 0.57 versus 1.98 ±
0.64 × 107/L, p = 0.0001). Moreover, mDC levels were
also significantly decreased in diabetic patients with
UAP compared to that of without CAD, when analyzed
as percentage of total white cells (0.13 ± 0.06% vs. 0.23
± 0.07%, p < 0.0001) or as absolute DCs (0.90 ± 0.48 ×
107/L vs. 1.63 ± 0.53 × 107/L, p < 0.0001). In contrast,
pDC numbers were not significantly altered (0.04 ±
0.03% versus 0.05 ± 0.02%, p > 0.05) between the two
groups. While compared with Normal the number of
Table 2 Concentration of circulating sFKN, IL-12 and IFN-a
Molecules Normal (n = 15) DM (n = 18) UAP (n = 18) DM + UAP (n = 21)
sFKN, pg/ml 477.1 ± 189.4 572.2 ± 165.0 729.0 ± 245.4*# 942.6 ± 364.6*#†
IL-12, pg/ml 45.7 ± 15.7 85.4 ± 35.6* 74.2 ± 32.4* 119.5 ± 44.1*#†
IFN-a, pg/ml 3.3 ± 3.7 2.0 ± 1.8 3.1 ± 2.7 2.9 ± 3.2
Results are expressed as mean ± SD. Normal: normal control subjects; DM: type 2 diabetic patients without CAD; UAP: non-diabetic patients with unstable angina
pectoris; DM + UAP: type 2 diabetic patients with UAP. *p < 0.05 versus Normal; #p < 0.05 versus DM; †p < 0.05 versus UAP.
Figure 2 Percentage and absolute numbers of peripheral blood total DCs (A,B), mDC(C,D) and pDC (E,F) in normal control (Normal, n
= 15), type 2 diabetic patients with (DM + UAP, n = 21) or without unstable angina pectoris(UAP) (DM, n = 18), and non-diabetic UAP
patients(UAP, n = 18). Horizontal long lines mean values. mDC: myeloid dendritic cell; pDC plasmacytoid dendritic cell.
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absolute pDC was significantly decreased in diabetic
patients with UAP (p = 0.02) (Figure 2).
The results also showed that percentage of total DCs
was significantly lower in diabetic patients with UAP
compared with non-diabetic UAP patients (0.17 ± 0.07
versus 0.22 ± 0.08%, p = 0.03). We also found the signif-
icant decrease of DCs and mDC in patients of UAP
compared with the Normal control subjects, which had
been reported before.
Assessment of the maturation of DC in the
different groups
The expressions of surface CD86 was marker that DCs
grew from immature state to maturation. Fluorescence-
activated cell sorter (FACS) analysis showed that the
expression of CD86 in patients with DM + UAP was the
highest among the four groups. It was also significantly
increased in patients with DM + UAP compared with
UAP. Differences between patients with DM and Nor-
mal were not significant (Figure 3). It indicated that the
state of DCs in patients with DM + UAP was more
mature than that in diabetic patients with no CAD and
normal control.
The capacity of DCs to stimulate T cells in the
different groups
To evaluate the functional activity, we next examined
the capacity of DCs to stimulate T cells in the different
groups by use of allogeneic MLRs. Compared with DM
and UAP, the proliferation of T cells stimulated by DCs
in DM + UAP was significantly increased. The capacity
of DCs in UAP was also significantly higher than that of
DM and Normal, and differences between patients with
DM and controls were not significant.(Figure 4A).
Simultaneously, DM + UAP had markedly increased
T-cell secretion level for IL-2 compared with DM (by
more than 3-fold at 1:5 DCs/T cells ratio) and UAP
(p = 0.01), consistent with T-cell activation.(Figure 4B).
Association of circulating mDC with inflammation and
atherogenic markers
Circulating mDC inversely correlated with serum FKN(r
= -0.268, p = 0.01) (Figure 5). No statistically significant
correlation was found between mDC and IL-12 level.
Discussion
The main findings in this study are the quantitative and
functional abnormalities observed in circulating DCs
detected in the diabetic patients with coronary artery
disease. Our study found that the number of circulating
total DCs and mDC in type 2 diabetic patients with
Figure 3 The immunophenotypic expressions of CD86 on
monocyte-derived DCs in subjects of Normal, DM, UAP and
DM + UAP. Flow cytometric analysis was performed for surface
CD86 expression examination. Normal: normal control subjects; DM:
type 2 diabetic patients without CAD; UAP: non-diabetic patients
with unstable angina pectoris; DM + UAP: type 2 diabetic patients
with UAP
Figure 4 Stimulating effects of monocyte-derived DCs on T
cells in MLRs. A: The incorporation of [3H] thymidine was
determinated by scintillation counting at 1:5, 1:10, 1:50 and 1:100
DCs:T cells ratio. B: The amounts of IL-2 in the supernatants of the
culture at 1:5 ratios was measured by ELISA. *P < 0.05 vs. Normal; #P
< 0.05 vs. DM; †P < 0.05 vs. UAP. MLR:mixed T lymphocytes reaction
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UAP decreased significantly compared with that with-
out CAD and nondiabetic patients with UAP, while
pDC was not significantly altered. Furthermore, func-
tional status of DCs in diabetic patients with UAP
were more mature and activated than diabetic patients
without CAD and none diabetic patients with UAP.
This was evidenced by the upregulation of costimula-
tory molecule CD86 and the enhanced capability of
DCs to stimulate T-cell proliferation and cytokine pro-
duction in allogeneic MLRs. Our data also showed
FKN, an important chemokine for accumulation of DC
in atherosclerotic plaque, was significantly increased in
diabetic patients with UAP compared with those with-
out CAD, and the decline in mDC inversely correlated
with the level of sFKN.
Diabetes is a widely accepted risk factor for athero-
sclerosis. Insulin resistance and hyperglycemia in type 2
diabetes mellitus are associated with a systemic proin-
flammatory state that promotes the development of
atherosclerosis[20,21], as evidenced by increases in the
concentration of proinflammatory cytokines, such as IL-
6, which plays a deleterious role in the development of
CAD and is an early indicator of incipient type 2 dia-
betes mellitus. The inflammatory response was greater
in diabetic than in nondiabetic plaques. Our recent in
vitro studies have reported that advanced glycosylation
end products (AGEs) [19], hyperinsulin[22] could
enhance DCs maturation and induce an antigen-specific
T cell activation. The present study in diabetic patients
further supported the role of DCs and its subsets on the
immune reactions in diabetic atherosclerosis and plaque
destabilization. CD86 is one of the mature markers of
DCs. Costimulation by the ligand CD86 and its receptor
CD28 on T cells is required for efficient T-cell stimula-
tion. We detected the expression level of CD86 in DCs
in different groups. We found that the expression level
of CD86 in DM + UAP patients was significantly higher
than in DM and UAP groups. Furthermore, co-culture
with DCs from DM + UAP patients evoked strong pro-
liferation of the T cells in comparison with the groups
of DM, UAP and Normal. DCs maturation and T-cell
stimulation in DM + CAD groups was paralled with
more IL-2 secretion, which is a marker of T-cell activa-
tion. Considering that DCs are most frequently observed
in atherosclerotic lesions enriched with T cells, the
increased expression of costimulatory molecules on DCs
and the capacity of T cell stimulation as well as cytokine
secretion seen in DM + UAP patients suggest that acti-
vated function of DCs in these patients is an important
mediator in immuno-inflammatory process as they are
responsible for T-cell activation and this cellular interac-
tion plays a role in plaque instability and vulnerability
towards rupture.
There are several possible reasons for the decline of
blood DCs in diabetic patients with unstable coronary
artery disease. Firstly, the inflammatory response was
greater in diabetic than in nondiabetic plaques and cir-
culating DCs were trafficked into inflamed vulnerable
plaques. Indeed, it has been reported that atherosclero-
tic arteries and vulnerable plaques contains more DCs
than unaffected arteries[10,23,24]. Yilmaz A et al[11]
recently described a significant decrease in circulating
mDC precursors in patients with acute coronary syn-
dromes, and this is associated with obvious accumula-
tion in mDC in vulnerable atherosclerotic plaques. The
observed more profound decrease in mDC than in
pDC might result from differences of their function
and the migratory response to chemotactic stimuli.
The hypothesis is supported by our data that com-
pared with diabetes without UAP, patients with dia-
betic unstable coronary disease have a significantly
higher level of FKN, which has been shown to be an
important chemokine for mDCs. pDC respond only to
the homeostatic CXCL-12, which attracts them into
lymphoid organs[25]. Stimuli known to accelerate
atherosclerosis in diabetes, such as oxidized LDLs[26],
AGEs[19], hypoxia[27]could role as antigens to induce
DCs to adhesion to and transmigration through
endothelial cells. Because mDC and pDC are consid-
ered to be specialized APCs preferentially inducing a
Th1 and Th2 response respectively[28], the migration
of circulating mDC into atherosclerotic plaque might
play an essential role in the initiation and regulation of
local immune reactions in plaque by polarizing naïve
T-helper cells into Th1 effector cells, thus enhancing a
Th1 response. Indeed, despite the decrease in circulat-
ing mDC, we found that serum IL-12 levels which is a
Th1 type cytokine and mainly secreted by mDCs was
significantly higher in the DM + UAP group compared
with those in the DM, UAP groups and Normal
Figure 5 A significant inverse correlation of circulating mDC
with serum levels of fractalkine. mDC: myeloid dendritic cell.
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controls, suggesting that mDCs in peripheral blood are
activated to secrete cytokines in diabetic patients with
UAP. Secondly, we can not exclude the possibility that
DCs after engulfing antigen in the arterial wall
migrated into regional lymph nodes where they acti-
vate T cells. Supporting this possibility are the immu-
nohistochemical observations showing that the number
of DCs in lymph nodes attached to atherosclerotic wall
segments exceed those in lymph nodes attached to
nonatherosclerotic arteries[29]. Thirdly, reduced gen-
eration of DCs in bone marrow, disturbed differentia-
tion of blood DCs from CD34 + precursors, might also
explain the decreased blood DCs numbers in diabetic
patients with CAD. Indeed, for example, although
TNF-a is required for DCs generation from CD34 +
precursors, its increased production by monocytes in
type 2 diabetes with CAD may adversely affect blood
DC differentiation from CD34 + precursors[30,31]. In
addition, the decreased DCs counts do not seem to be
related to suppressed myelopoiesis since patients of in
type 2 diabetes with CAD in our study had similar
monocyte counts to those without CAD and controls.
Taken together, our study showed a significant
decrease in circulating total DCs and mDC in type 2
diabetic patients with UAP, and functional status of
DCs in diabetic patients with UAP were more mature
and activated than diabetic patients without CAD and
none diabetic patients with UAP. The decline in mDC
inversely correlated with the serum level of FKN
which has been shown to be an important chemokine
for accumulation of DCs in the atherosclerotic plaque.
Because DCs are most frequently observed in athero-
sclerotic lesions enriched with T cells and are strong
T-cell stimulators, our results suggest that the number
and functional changes of DCs in diabetic patients
with UAP might plays an important role in this cellu-
lar interaction, leading to plaque instability and vul-
nerability towards rupture. Because of the limitation
in small population of our study, furthered detailed
studies with larger cohort will no doubt lead to
improved knowledge regarding the role DCs play in
diabetic atherosclerotic lesions. Moreover, monitoring
of DCs and its subsets may represent a novel strategy
to detect acute coronary syndrome in human type 2
diabetes.
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